A Phase II Study of Continuous Versus Syncopated Dosing of CC-5013 for the Treatment of Refractory Multiple Myeloma
Status:
Completed
Trial end date:
2006-10-01
Target enrollment:
Participant gender:
Summary
To evaluate the response rate, response duration, and survival of patients treated with
CC-5013 in a chronic dosing schedule versus a syncopated dosing schedule.